(Q35062816)

6 August 2017

0 references

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report (English)

1 reference

6 August 2017

0 references

0 references

Yue Li

1

1 reference

6 August 2017

Zelong Han

2

1 reference

6 August 2017

Xianfei Wang

3

1 reference

6 August 2017

Zhihui Mo

4

1 reference

6 August 2017

Wei Zhang

5

1 reference

6 August 2017

Aimin Li

6

1 reference

6 August 2017

Side Liu

7

1 reference

6 August 2017

9 December 2013

1 reference

6 August 2017

1 reference

6 August 2017

13

1 reference

6 August 2017

167

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-230x-13-167

6 August 2017

0 references

cites work

Differential diagnosis and management of Behçet syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

New insights into the pathogenesis of Behçet's disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

New insights in the clinical understanding of Behçet's disease.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

The use of biologic agents in the treatment of ocular manifestations of Behcet's disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Thalidomide: current and potential clinical applications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Behçet's disease: global epidemiology of an Old Silk Road disease

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Combination therapy including pentoxifylline for entero-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Intestinal Behçet's disease: epidemiology, pathophysiology and potential of mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Behçet's disease in UK children: clinical features and treatment including thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4029173

Thalidomide Responsiveness in an Infant With Behçet's Syndrome

27 September 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-13-167

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

[Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease]

1 reference

12 December 2020

Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab

1 reference

12 December 2020

Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-230X-13-167

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference

6 August 2017

1 reference